|
Here, as elsewhere, innovation outpaces translation. The science advances faster than the systems designed to deliver it. The consequence is avoidable delay, inefficiency, and inequity - not because breakthroughs are lacking, but because the pathways to routine use are fragile.
Solving this does not require less innovation. It requires stronger, more scalable mechanisms for moving discovery into everyday clinical practice.
The cost of innovation theatre
Healthcare systems are not passive victims of the translation gap. They often sustain it. Procurement and commissioning processes are frequently fragmented, opaque, and slow. Decision-making is dispersed across committees with misaligned incentives and unclear ownership. Risk aversion, while often justified, becomes paralysing when no one is empowered to decide.
In this environment, pilots proliferate because they feel safe. They allow organisations to signal openness to innovation without committing to adoption. Over time, pilots become a holding pattern - activity without accountability, motion without progress.
The result is innovation theatre. Start-ups cycle through endless proofs-of-concept. Providers host demonstrations that never translate into decisions. Success is measured by participation rather than impact, and real-world benefit is deferred, sometimes indefinitely.
Translation demands something harder than enthusiasm. It requires leadership willing to make choices: scale what works, stop what does not, and accept measured, governed risk. Without that decisiveness, innovation remains performative - and patients see little benefit.
Industry’s responsibility in the translation gap
It is convenient to place responsibility for the translation gap on healthcare systems and regulators. Industry must confront its own role. Too many MedTech and digital health companies still approach healthcare as if success were primarily a function of technical differentiation, compelling demos, and persuasive selling. In doing so, they mistake interest for adoption and pilots for progress.
Too few teams invest early in understanding the lived realities of clinical work: time pressure, risk burden, workarounds, and constant trade-offs. Even fewer grapple with service delivery constraints, procurement dynamics, or the long-term economics of adoption and support. The result is predictable: products that function technically but fail operationally.
Translation cannot be delegated to a sales team once the product is “done”. It is not a messaging problem. It is a systems problem spanning regulation, workflow, incentives, liability, governance, and trust - and it cannot be solved late.
Companies that treat translation as a core strategic capability - designed in from day one - are the ones most likely to escape pilots, achieve scale, and deliver lasting impact.
Translation as a strategic capability
The next advantage in healthcare will not belong to those with the best technology. It will belong to those who can get technology adopted. Translation is not an execution detail. It is a strategic capability.
For investors, executives and directors, that means looking beyond novelty. Winning teams combine technical strength with regulatory fluency, clinical credibility, operational understanding and commercial discipline. They produce evidence that answers the questions buyers and operators face: will this work in pressured environments, fit existing workflows, clear budget hurdles and improve outcomes without creating new friction?
That is where many organisations still fall short. Products are too often designed around technical performance rather than institutional fit. Yet adoption depends less on what a tool can do in theory than on whether people can use it, trust it and take responsibility for it in practice.
Translation is therefore as much organisational as technological. It requires leadership willing to absorb short-term disruption in pursuit of long-term gains. Those that build for real-world constraints will scale. Those that do not will continue to confuse innovation with impact.
Change, not just tools
Healthcare organisations are not blank slates onto which new technologies can be dropped. They are complex systems in which any new tool alters workflows, responsibilities, risk allocation and decision-making. Adoption is therefore not a deployment exercise. It is a change-management problem.
That is where value is often lost. Training, operational support, governance and leadership attention are routinely treated as secondary to product build or launch. In practice, they determine whether a technology becomes embedded or fades after initial enthusiasm. Durable impact comes not at implementation, but through sustained use.
AI sharpens the point. The technical progress is real, but benchmark performance will not by itself determine commercial value. Tools must fit workflows, support accountability, earn clinical trust and operate within governance and liability constraints. A model can perform well in validation and still fail in practice if it adds friction or ambiguity.
For investors, executives and directors, the lesson is straightforward: healthcare value is created not by tools alone, but by organisations able to absorb and sustain change.
What taking translation seriously looks like
Taking translation seriously means changing what the sector rewards. That starts with a simple shift: judging innovation not only by novelty or technical performance, but by adoption readiness.
That means backing teams that can navigate regulation, fit products into workflows and show measurable impact in real settings. It means providers engaging earlier with innovators, with clearer ownership and shared accountability. It also means treating pilots as decision tools, not theatre: time-bound, outcome-driven and designed to support scale or stop choices.
The broader point is cultural as much as operational. Healthcare spends too much time celebrating novelty and too little on disciplined adoption. Translation is not the final stage of innovation. It is the part that determines whether innovation creates value.
A different definition of progress
Healthcare rarely advances through dramatic disruption. Progress is usually cumulative - built through integration rather than replacement, refinement rather than rupture. This is not a failure of ambition. It is the consequence of a system that prioritises safety, trust, accountability, and continuity of care. In healthcare, change that endures is change that fits.
The organisations that succeed will be those that recognise this reality and work with it, not against it. They will resist transformation narratives that promise speed at the expense of credibility. Instead, they will focus on pragmatic progress: embedding new capabilities into existing systems, reducing friction, and improving outcomes step by step.
This translation challenge is visible across every engagement. The innovations that make it through are rarely the most radical. They are the ones that respect constraints rather than dismiss them, align incentives rather than fight them, and earn trust rather than demand it. They treat translation not as friction to overcome, but as the core work of healthcare innovation itself.
Takeaways
Healthcare does not need more ideas, more platforms, or louder claims of disruption. It needs leaders willing to confront where innovation fails - at the point of adoption. The bottleneck is no longer discovery - it is translation, and translation is a strategic discipline: aligning incentives, designing for real workflows, producing decision-grade evidence, and leading operational change with the courage to absorb short-term friction for long-term outcomes. Until that becomes the operating system - not a late-stage add-on - breakthroughs will keep outpacing impact, and incumbents will keep defending the status quo through inertia and politics. The next era will not be defined by who invents first, but by who delivers last: those who build translation capability will shape care, markets, and outcomes; those who do not will continue to confuse activity with progress. Innovation is abundant. Impact is not. The future belongs to those who close that gap.
|
1 day, 16 hours ago
Facebook
Twitter
Google+
LinkedIn
